Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Recipient : University of Iowa
Deal Size : Inapplicable
Deal Type : Inapplicable
Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Recipient : University of Iowa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Baiya Phytopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials
Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 29, 2022
Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Baiya Phytopharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 3M-052,Potassium Alum
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : IDRI
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including b...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : 3M-052,Potassium Alum
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : IDRI
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase III
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of Patient Preoperative Preps In-vivo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2021
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sls Toothpaste
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 23, 2020
Lead Product(s) : Sls Toothpaste
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Recipient : Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Recipient : Brigham and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NPWTi-d
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Recipient : KCI USA, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 29, 2018
Lead Product(s) : NPWTi-d
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Recipient : KCI USA, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vanish XT
Therapeutic Area : Dental and Oral Health
Study Phase : Phase IV
Recipient : University of Nebraska
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 18, 2018
Lead Product(s) : Vanish XT
Therapeutic Area : Dental and Oral Health
Highest Development Status : Phase IV
Recipient : University of Nebraska
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Study Phase : Phase II
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
In Vivo Preoperative Skin Preparation Efficacy Study Within a Defined Product Coverage Area
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2018
Lead Product(s) : Chlorhexidine Gluconate
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2017
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Solventum US LLC
Deal Size : Inapplicable
Deal Type : Inapplicable